Moderna, Inc.(MRNA)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
MRNA | 78.44 B | - | 2.10% | -141.43% | -$7.82 | -39.00% | 0.19x | 0.00% | $208.90 | $22.28 |
BIIB | 32.82 B | 40.03x | 3.40% | 8.32% | $5.55 | 4.58% | 0.44x | 0.00% | $230.49 | $138.00 |
UTHR | 23.38 B | 19.53x | -1.90% | 41.56% | $27.91 | 19.32% | - | 0.00% | $609.35 | $409.07 |
INCY | 22.99 B | 14.97x | 37.70% | 27.71% | $7.58 | 30.67% | 0.60x | 0.00% | $132.60 | $82.82 |
INSM | 22.22 B | - | 296.10% | -76.94% | -$4.06 | -87.22% | 0.98x | 0.00% | $212.75 | $90.39 |
Peer Valuation & Performance Analysis
Peer group analysis for Moderna, Inc. (MRNA) compared to its primary competitors (including BIIB, UTHR, INCY) reveals distinct metrics. MRNA trades at a valuation discount relative to its competitors, with a P/E ratio of -25.1x versus the peer average of 12.4x (representing a 303% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, MRNA's revenue growth of 2.1% lags behind the peer average of 83.8%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of -141.4% is below the peer average of 0.2%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• MRNA ranks #0 in P/E ratio, #4 in revenue growth, and #5 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-07 | $183.65 | $197.69 | $182.50 | $196.48 | 14,614,400 | +4.81% |
| 2026-10-06 | $202.09 | $212.22 | $186.64 | $187.46 | 18,794,800 | -7.75% |
| 2026-10-05 | $191.41 | $205.77 | $185.90 | $203.21 | 19,313,300 | +6.95% |
| 2026-10-02 | $190.26 | $193.72 | $183.28 | $190.01 | 10,289,500 | +0.57% |
| 2026-10-01 | $186.61 | $201.00 | $186.01 | $188.94 | 15,437,000 | -1.89% |
| 2026-09-30 | $186.55 | $196.83 | $184.58 | $192.57 | 20,649,500 | -5.35% |
| 2026-09-29 | $197.78 | $208.90 | $190.00 | $203.46 | 13,277,900 | +3.13% |
| 2026-09-28 | $195.16 | $199.82 | $189.10 | $197.28 | 13,359,600 | -0.80% |
| 2026-09-25 | $195.34 | $202.67 | $192.51 | $198.88 | 13,945,000 | +2.08% |
| 2026-09-24 | $180.60 | $195.71 | $180.39 | $194.82 | 16,605,500 | +6.98% |
| 2026-09-23 | $183.41 | $192.31 | $181.30 | $182.11 | 17,727,800 | -0.25% |
| 2026-09-22 | $168.50 | $187.20 | $168.30 | $182.56 | 24,033,900 | +5.56% |
| 2026-09-21 | $161.05 | $176.86 | $159.06 | $172.94 | 21,018,300 | +12.27% |
| 2026-09-18 | $158.35 | $159.79 | $150.26 | $154.04 | 20,229,600 | -2.55% |
| 2026-09-17 | $152.50 | $161.96 | $149.50 | $158.07 | 19,175,000 | +8.55% |
Explore More Analysis for MRNA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.